BMO Capital Downgrades Facet Biotech (FACT) to Market Perform
FACT Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
BMO Capital downgrades Facet Biotech (Nasdaq: FACT) from Outperform to Market Perform. Price target $27.
To see all the upgrades/downgrades on shares of FACT, visit our Analyst Ratings page.
Facet Biotech Corporation (Facet Biotech) is a biotechnology company dedicated to advancing its pipeline of several clinical-stage products and expanding and deriving value from its protein engineering platform technologies to improve the clinical performance of protein therapeutics.
To see all the upgrades/downgrades on shares of FACT, visit our Analyst Ratings page.
Facet Biotech Corporation (Facet Biotech) is a biotechnology company dedicated to advancing its pipeline of several clinical-stage products and expanding and deriving value from its protein engineering platform technologies to improve the clinical performance of protein therapeutics.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Societe Generale Downgrades Baker Hughes (BHI) to Hold
- Goldman Sachs Downgrades General Dynamics Corp. (GD) to Sell; Gulfstream Risk
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
